Kidney study findings could boost the market for embolic protection devices
This article was originally published in Clinica
Executive Summary
In what could boost sales of coronary embolic protection devices, an independent study has found that such devices may also be used to successfully remove harmful emboli in blood vessels supplying the kidney during routine angioplasty and stenting. In current procedures, emboli - abnormal particles such as blood clots that clog-up the vessel - can become dislodged and cause further harm elsewhere. If the devices can gain worldwide approval for this new indication, their use could be expanded to a further 100,000 procedures a year.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.